GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody-positive SLE who are receiving standard therapy. Systemic Lupus Erythematosus (SLE) is the most common form of lupus, a chronic, incurable autoimmune disease producing autoantibodies that can attack almost any system in the body. The approval marks the first subcutaneous self-injection treatment option for patients with SLE.
{iframe}http://pipelinereview.com/index.php/2017072265322/Antibodies/GSK-receives-FDA-approval-for-a-new-self-injectable-formulation-of-Benlysta-belimumab-for-systemic-lupus-erythematosus.html{/iframe}